08:49 AM EDT, 04/22/2024 (MT Newswires) -- Lantern Pharma ( LTRN ) said Monday it has received regulatory approval to expand its Harmonic trial in Japan and Taiwan, a phase 2 clinical study of LP-300 in non-small cell lung cancer in never-smokers, the company added.

LP-300, a therapeutic to treat relapsed and inoperable primary adenocarcinoma of the lung given in combination with chemotherapy, has generally been "well tolerated" in multiple clinical trials, Lantern said.

Shares of the company were up 5% in recent Monday premarket activity.